All storiesMetabolic health

Vitamin C linked to fewer deaths in blood disorder trial

A phase 2 trial found that daily vitamin C did not reduce abnormal blood cell growth in precancerous or low-risk blood cancers, but it was associated with improved inflammation markers and fewer serious complications. An exploratory follow-up suggested fewer deaths with vitamin C compared to placebo.

NeoMD Editors · 2026-10-11

For information, not personal medical advice. Discuss treatment decisions with a qualified clinician.

The quick read

Key takeaways

Vitamin C did not slow abnormal blood cell growth in people with precancerous or low-risk blood cancers.
Participants taking vitamin C showed favourable changes in inflammation and fewer serious complications.
An exploratory analysis found fewer deaths among those receiving vitamin C, but this requires cautious interpretation and further study.

Editorial illustration for Vitamin C linked to fewer deaths in blood disorder trial — AI-generated editorial illustration.

What the trial investigated: Researchers studied whether vitamin C could affect disease progression or outcomes in people with precancerous or low-risk blood cancers. Participants took daily vitamin C or placebo, and scientists monitored abnormal blood cell growth, inflammation, complications, and deaths.

Key findings: The trial did not show that vitamin C slowed the abnormal growth of blood cells, which are a hallmark of these blood disorders. However, those who took vitamin C showed favorable changes in inflammation, and fewer serious complications were reported. An exploratory follow-up also observed fewer deaths among participants receiving vitamin C compared to those on placebo.

Supporting editorial illustration for Vitamin C linked to fewer deaths in blood disorder trial — AI-generated editorial illustration.

Limitations: This was a phase 2 trial, which is typically small and designed to evaluate safety and biological effects rather than prove clinical benefits. The reduction in deaths was found in an exploratory analysis, which means it was not the primary goal and should be interpreted cautiously. Whether the changes observed translate into long-term benefits remains uncertain, and more research is needed to confirm these findings.

Possible implications: While vitamin C did not affect abnormal cell growth in this trial, its impact on inflammation and serious complications could be important if confirmed by larger studies. The exploratory finding of fewer deaths is intriguing but requires further investigation before vitamin C could be recommended as a treatment component for these blood disorders.

Source: ScienceDaily Medical